Abstract:Objectives The Rho guanosine triphosphatases (Rho GTPases)family, including RhoA, plays an important part in angiotensin II (Ang II)-mediated cardiac fibrosis. Farnesyl pyrophosphate synthase (FPPS)-catalysed isoprenoid intermediates are important for activation of RhoA. Evidence is accumulated for crucial role of FPPS in the process of cardiac hypertrophy and fibrosis. The present study was designed to investigate the role of FPPS in cardiac fibrosis induced by Ang II. Methods In vivo and in vitro model of cardiac fibrosis were settled by Ang II. FPPS expression was measured by Western blot and qRT-PCR. Cultured neonatal cardiac fibroblasts (NCFs) proliferation was determined by Cell Counting Kit-8 assay and Edu assay. The role of FPPS was both estimated by FPPS inhibitor (zolendronate) and RNA interference (RNAi) against FPPS in NCFs. RhoA activation was evaluated by pull-down assay. Results First, We demonstrated that FPPS expression was elevated both in the in vitro model of NCFs and in the in vivo model of myocardium by Ang II. Then, FPPS inhibition by zolendronate decreased cardiac fibrosis marker gene of collagen I, collagen III and transforming growth factor β1(TGFβ1). Furthermore, the inhibition was reversed with geranylgerananyol (GGOH) and mimicked by Rho inhibitor, suggesting that the anti-fibrotic effect of zolendronate might be via limitation of RhoA geranylgeranylation. Pull-down assay showed that zolendronate reduced active RhoA by Ang II, which was also partially antagonised by GGOH. In addition, FPPS specifically knocking-down prevented expression of collagen I, collagen II and TGF β1, as well as prevented elevated RhoA activity by Ang II compared with non-silencing controls. Conclusions This study reveals FPPS elevation in Ang II-induced cardiac fibrosis model both in vivo and in vitro model. The inhibition and knockdown of FPPS reduces RhoA activation by diminishing geranylgeranylation which prevents Ang II-induced collagen I, collagen III, TGF β1 expression.

Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats.

Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats.

Chronic inhibition of farnesyl pyrophosphate synthase improves endothelial function in spontaneously hypertensive rats.

Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo.

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Norepinephrine–induced Fibrotic Responses in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats

Inhibition of Farnesylpyrophosphate Synthase Prevents Angiotensin II-induced Hypertrophic Responses in Rat Neonatal Cardiomyocytes: Involvement of the RhoA/Rho Kinase Pathway

Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy.

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Farnesyl Pyrophosphate Synthase Inhibitor, Ibandronate, Improves Endothelial Function in Spontaneously Hypertensive Rats

Alendronate prevents angiotensin II-induced collagen I production through geranylgeranylation-dependent RhoA/Rho kinase activation in cardiac fibroblasts.

Cardiac-specific Overexpression of Farnesyl Pyrophosphate Synthase Induces Cardiac Hypertrophy and Dysfunction in Mice.

Prevention of myocardial fibrosis by using nitrendipine to the spontaneously hypertensive rats

GW24-e2448 Knockdown of Farnesyl Pyrophosphate Synthase Prevents Cardiac Fibrosis of Spontaneously Hypertensive Ratsin Vivo

Inhibition of Farnesyl Pyrophosphate Synthase Prevents Angiotensin II-induced Cardiac Fibrosis in Vitro.

Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension.

Abstract 523: Myocardial Hypertrophy and Fibrosis Regulated by Nogo-ROCK-norepinephrine Transporter Signaling Pathway in Spontaneously Hypertensive Rats

Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats

GW24-e2384 the Role of Farnesyl Pyrophosphate Synthase in Angiotensin II-induced Cardiac Fibrosis

Effects of Eplerenone on Vascular Remodeling in Spontaneously Hypertensive Rats not Related with Blood Pressure